drugset / Trial / NCT00145210

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

NCT00145210

Phase 3 Completed 630 enrolled Mylan Bertek Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension.

Timeline

Start
2005-04
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Atenolol Other / unclassified
Subject Nebivolol Other / unclassified

Indications